Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abcellera Biologics Inc (NQ: ABCL )

3.840 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 152
Open 3.840
Bid (Size) 3.840 (11)
Ask (Size) 3.910 (1)
Prev. Close 3.840
Today's Range 3.840 - 3.840
52wk Range 3.620 - 8.050
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-32.98%
-32.98%
1 Month
-13.51%
-13.51%
3 Month
-31.31%
-31.31%
6 Month
-4.95%
-4.95%
1 Year
-43.28%
-43.28%

More News

Read More
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
From AbCellera Biologics Inc.
Via Business Wire
Recap: AbCellera Biologics Q4 Earnings
Via Benzinga
The 7 Best Penny Stocks to Buy in Q2 2024
Via InvestorPlace
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
From AbCellera Biologics Inc.
Via Business Wire
Recap: These 7 Artificial Intelligence (AI) Stock Categories Had Returns From +2 To +15% In February
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Via Talk Markets
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Via InvestorPlace
AbCellera Announces Resignation of Board Member
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at Upcoming Investor Conferences in March
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
AbCellera Reports Full Year 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Earnings Scheduled For February 20, 2024
Via Benzinga
These 9 AI Stock Categories Performed From +18% To -4% Last Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
From AbCellera Biologics Inc.
Via Business Wire
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond
Via The Motley Fool
3 Growth Stocks That Could Go Parabolic in 2024
Via The Motley Fool
AI-Focused Drug Discovery Stocks Index Up 26% In December
Via Talk Markets
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
From AbCellera Biologics Inc.
Via Business Wire
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.